Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets.
Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, Soong DYH, Cotechini T, Anur P, Lin EY, Fidanza A, Lopez-Yrigoyen M, Millar MR, Urman A, Ai Z, Spellman PT, Hwang ES, Dixon JM, Wiechmann L, Coussens LM, Smith HO, Pollard JW. · 2019
Read Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. by Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, Soong DYH, Cotechini T, Anur P, Lin EY, Fidanza A, Lopez-Yrigoyen M, Millar MR, Urman A, Ai Z, Spellman PT, Hwang ES, Dixon JM, Wiechmann L, Coussens LM, Smith HO, Pollard JW. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6472943.txt.
Introduction
Cassetta and co-authors map gene activity in the macrophages and blood monocytes of breast and endometrial cancer, showing that cancer retrains both, body-wide and on the spot. Profiles of the macrophages inside tumors differed from blood monocytes and from the resident cells of the matching healthy tissue.
A gene signature from breast tumor macrophages sat mostly in harsh subtypes and predicted shorter survival in public tumor data. The team also caught a self-feeding loop: tumor cells and macrophages trade TNF-α, CCL8, and CSF1 signals, raising SIGLEC1 and pulling in more monocytes. SIGLEC1 plus CCL8 together marked a poor outlook on their own, marking the loop as a target worth attacking.
Catalog record
| CREATOR | Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, Soong DYH, Cotechini T, Anur P, Lin EY, Fidanza A, Lopez-Yrigoyen M, Millar MR, Urman A, Ai Z, Spellman PT, Hwang ES, Dixon JM, Wiechmann L, Coussens LM, Smith HO, Pollard JW. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 106 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets By Luca Cassetta, Stamatina Fragkogianni, Andrew H. Sims, Agnieszka Swierczak, Lesley M. Forrester, Hui Zhang, Daniel Y.H. Soong, Tiziana Cotechini, Pavana Anur, Elaine Y. Lin, Antonella Fidanza, Martha Lopez-Yrigoyen Published in: Cancer Cell DOI: 10.1016/j.ccell.2019.02.009 ABSTRACT Summary The roles of tumor-associated macrophages (TAMs) and circulating monocytes in human cancer are poorly understood. Here, we show that monocyte subpopulation distribution and transcriptomes are significantly altered by the presence of endometrial and breast cancer. Furthermore, TAMs from endometrial and breast cancers are transcriptionally distinct from monocytes and their respective tissue-resident macrophages. We identified a breast TAM signature that is highly enriched in aggressive breast cancer subtypes and associated with shorter disease-specific survival. We also identified an auto-regulatory loop between TAMs and cancer cells driven by tumor necrosis factor alpha involving SIGLEC1 and CCL8, which is self-reinforcing through the production of CSF1. Together these data provide direct evidence that monocyte and macrophage transcriptional landscapes are perturbed by cancer, reflecting patient outcomes. SIGNIFICANCE Human breast and endometrial cancer systemically alter circulating monocytes and, from these cells, a transcriptional signature recognizing cancer was determined. Cancer locally educates tumor-associated macrophages (TAMs) such that they are different from monocytes, from tissue-resident macrophages, and from each other. A “cancer-specific immune signature” derived from breast cancer TAMs is prognostic for poor disease-specific survival in publically available datasets from whole tumors. Breast cancer TAMs express CCL8, which is chemotactic for monocytes and drives a positive regulatory loop between cancer cells and TAMs through CSF1 and TNF-α, which upregulates SIGLEC1. SIGLEC1 and CCL8 expression together are independent prognostic markers for poor survival. These data suggest that cancer-specific targeting of TAMs could be of therapeutic benefit. INTRODUCTION Tumors evolve as ecosystems consisting of tumor, stromal, and infiltrating immune cells. Macrophages are major components of this ecosystem. In mouse models, different subpopulations of tumor-associated macrophages (TAMs) promote angiogenesis, tumor cell invasion, intravasation, and, at the metastatic site, tumor cell extravasation and persistent growth, and suppress cytolytic T cell responses (Cassetta and Pollard, 2018). In homeostasis, tissue macrophages have different origins; however, in most cancer models, TAMs are recruited from bone marrow progenitors known as monocytes (Arwert et al., 2018, Franklin et al., 2014, Qian et al., 2011). These monocytes are termed classical (human CD14++CD16− and mouse CD11b+Ly6C+) and non-classical (human CD14+CD16+; mouse CD11b+Ly6C−). The classical population is recruited as the tumor progresses and differentiates in situ to TAMs, often via a CCL2-CCR2 chemokine signaling pathway. Inhibition of CCR2 signaling blocks TAM recruitment and thus inhibits tumor cell seeding and persistent growth, improving the survival of mice (Qian et al., 2011). The pro-tumoral behavior of monocytes and TAMs in mouse models has made them attractive therapeutic targets. Targeting strategies include inhibiting monocyte recruitment, depletion of TAMs, and functional/phenotypic reprogramming (Cassetta and Pollard, 2018). These therapies, however, are limited by the lack of TAM-specific markers (Williams et al., 2016), as well as our limited understanding of their functions in human cancers (Takeya and Komohara, 2016). We hypothesize that human breast and endometrial cancer will have a significant impact on circulating monocytes and their progeny TAMs, which will indicate signaling pathways, therapeutic and diagnostic approaches, as well as prognostic biomarkers. RESULTS Cancer Alters the Transcriptome of Human Monocytes We performed bulk RNA sequencing (RNA-seq) on total monocytes isolated from women with breast (n = 32) or endometrial (n = 3) cancer and from healthy controls (n = 45) and (Figures S1A and S1B). Although there are outliers, principal-component analysis (PCA) and hierarchical clustering segregated the transcriptomic profiles of normal monocytes (Mo) from breast or endometrial cancer patient monocytes (Figures 1A and 1B). Thus, we designated cancer monocytes as tumor-educated monocytes (TEMo). Limma differential expression analysis (DEA) revealed 865 differentially expressed genes (DEGs) in breast TEMo compared with Mo (543 upregulated and 322 downregulated; false discovery rate [FDR] ≤ 0.05, Table S1) and 997 DEGs in endometrial TEMo compared with Mo (498 upregulated and 499 downregulated; FDR ≤ 0.05, Table S1). Because of the limited size of endometrial TEMo samples, we focused our downstream analysis on the breast TEMo. Gene ontology (GO) analysis reported a number of enriched terms, such as cell migration, angiogenesis, cell communication, and apoptotic process (Figure 1C). A number of genes encoding transmembrane receptors, soluble factors, transcription factors, and enzymes were deregulated, including increased expression of transcripts encoding immune regulatory receptors (CD200R1), pro-apoptotic molecules (TNFSF10), and pro-angiogenic factors (HGF and ANGPT1) (Figure 1D). qRT-PCR of monocytic RNA derived from an independent breast cancer cohort confirmed significant increased expression of these genes (Figure 1E).Figure 1Cancer Alters the Transcriptome of Human Monocytes(A) Principal-component analysis (PCA) plot of n = 12,157 genes expressed in monocytes from healthy individuals (Mo) (n = 45) and TEMo from cancer patients (n = 35; breast cancer [BrCa] = 32; endometrial cancer [EnCa] = 3).(B) Hierarchical clustering of all differentially expressed genes (DEGs) between Mo and TEMo. Expression values are Z score transformed. Samples were clustered using complete linkage and Euclidean distance.(C) Gene ontology (GO) analysis of DEGs between TEMo and Mo (blue, downregulated genes; red, upregulated genes).(D) Bar plot of selected DEGs in TEMo (FDR <= 0.05).(E) Expression of CD200R1, TNFSF10, HGF, and ANGPT1 mRNA in Mo and breast TEMo (n = 3–5; independent from the RNA-seq cohort).(F) Relative distribution of non-classical monocytes from healthy controls and BrCa and EnCa patients determined by flow cytometry shown as percentage in the monocyte gate. Cohort 1: Mo, n = 31, BrCa TEMo, n = 22, EnCa TEMo, n = 12. Cohort 2, BrCa and controls only: Mo, n = 18, TEMo, n = 33.(G) ELISA quantification of CX3CL1 and CCL2 levels in the sera of control (CTR) (n = 15) and BrCa patients (n = 45).(H) Expression of CX3CR1 and CCR2 in Mo (n = 10) and breast TEMo (n = 31). Data are expressed as geometric mean (Geo mean).(I and J) Confusion matrix (I) and summary of results of Recursive Feature Elimination with Random Forest (RFE-RF) classification on the testing set (n = 22) for breast TEMo (J).(K) Receiver operating characteristic curves of RFE-RF classification in the training and test set.(E and H) Data depicted as means ± SEM; (F and G) horizontal bars represent the mean of the individual values ± SD; (E–H) Student's t test; ∗p < 0.01, ∗∗p < 0.001, ∗∗∗p < 0.0001.See also Figure S1 and Table S1. To understand if this shift in TEMo transcriptomes was driven by a specific subpopulation, we analyzed classical and non-classical monocytes from two independent cancer cohorts as well as healthy women (Figures 1F and S1C–S1E; Table S1). Non-classical monocytes from cancer patients exhibited a significant expansion compared with healthy controls in both cohorts without significant differences between endometrial and breast cancer patients (Figure 1F). This expansion was associated with a significant increase in CX3CL1 and reduction of CCL2 in cancer patients' sera (Figure 1G). The expression level of the main receptor of CCL2, CCR2, did not change among subpopulations and conditions, although CX3CR1, the CX3CL1 receptor, was significantly downregulated in classical monocytes from cancer patients compared with controls, consistent with the alterations in monocytic populations (Figure 1H). We isolated non-classical monocytes from 13 cancer patients (n